StockNews.AI
ENSC
StockNews.AI
56 days

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

1. Ensysce announces full enrollment in PF614-MPAR-102 clinical study. 2. PF614-MPAR holds FDA's Breakthrough Therapy designation for innovative overdose protection. 3. NIDA grant continues to support the clinical program into 2027. 4. CEO remarks on potential to reshape opioid safety in pain relief. 5. Ensysce leverages proprietary TAAP™ and MPAR® technologies to combat opioid abuse.

7m saved
Insight
Article

FAQ

Why Bullish?

The news highlights critical milestones in clinical trials and FDA designation, suggesting progress.

How important is it?

The article underlines advancements in Ensysce’s pipeline, influencing investor confidence and stock value.

Why Long Term?

Success in trials could lead to regulatory approval and commercial success in several years.

Related Companies

PFEJNJAMGN
~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Development Program ~ Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology.PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is uniquely engineered using Ensysce's proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies. These platforms enable PF614-MPAR to maintain therapeutic efficacy while delivering built-in overdose protection when doses exceed prescribed amounts, whether accidentally or intentionally.A three-year grant from the National Institute on Drug Abuse (NIDA), with second year funding recently announced1, continues to support this program through May 2027. This support will accelerate the clinical development of PF614-MPAR and could help launch a new era in pain relief with overdose protection."This is more than a study milestone - it's a turning point in pain medicine," said Dr. Lynn Kirkpatrick, CEO of Ensysce. "We are moving closer to delivering a new class of opioid that not only relieves pain but also shields patients from the danger of overdose. We believe PF614-MPAR has the potential to redefine opioid safety for millions of patients."1The research is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number UO1DA059791.About Ensysce BiosciencesEnsysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.Forward-Looking StatementsStatements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.Ensysce Biosciences Company Contact:Lynn Kirkpatrick, Ph.D.Chief Executive Officer(858) 263-4196Ensysce Biosciences Investor Relations Contact:Shannon DevineMZ North America Main: 203-741-8811[email protected]SOURCE: Ensysce Biosciences Inc.

Related News